|
#2252
|
|
ENTA sues PFE for patent infringement wrt Paxlovid:
|
DewDiligence
|
06/21/2022 09:01:14 PM |
|
#2261
|
|
All of those reasons plus the scary stuff
|
DewDiligence
|
07/05/2022 11:36:55 AM |
|
#2260
|
|
ENTA broke $51 this morning. The stock price
|
vinmantoo
|
07/05/2022 11:18:42 AM |
|
#2259
|
|
The Canada approval is for the pediatric market
|
vinmantoo
|
06/22/2022 04:20:33 PM |
|
#2258
|
|
The Canada approval is for the pediatric market
|
DewDiligence
|
06/22/2022 02:41:43 PM |
|
#2257
|
|
It may be as simple as Enanta was
|
willyw
|
06/22/2022 01:12:52 PM |
|
#2256
|
|
I just saw that Canada approved the use
|
vinmantoo
|
06/22/2022 12:47:45 PM |
|
#2255
|
|
Wow!
Thanks for providing the link as it gets
|
willyw
|
06/21/2022 05:27:19 PM |
|
#2254
|
|
(ENTA)—PFE’s guidance for 2022 Paxlovid sales is $22B,
|
DewDiligence
|
06/21/2022 05:17:46 PM |
|
#2253
|
|
Addendum—ENTA is not seeking an injunction against Paxlovid,
|
DewDiligence
|
06/21/2022 05:11:42 PM |
|
#2252
|
|
ENTA sues PFE for patent infringement wrt Paxlovid:
|
DewDiligence
|
06/21/2022 05:01:14 PM |
|
#2251
|
|
ENTA’s CEO exercised and held $140K of stock
|
DewDiligence
|
06/21/2022 04:10:56 PM |
|
#2250
|
|
EDP-235 data release will occur in July (not June).
|
DewDiligence
|
06/09/2022 11:57:00 AM |
|
#2249
|
|
Thank you sir.
|
rwwine
|
05/24/2022 10:40:32 PM |
|
#2248
|
|
ENTA has committed to releasing some or all
|
DewDiligence
|
05/24/2022 09:18:08 PM |
|
#2247
|
|
Apropos the safety data set for EDP-235.
|
rwwine
|
05/24/2022 06:16:26 PM |
|
#2246
|
|
Thanks Dew. The second to last slide (#29)
|
vinmantoo
|
05/19/2022 08:56:12 PM |
|
#2245
|
|
Follow-up—After all the commotion, ENTA closed down only
|
DewDiligence
|
05/19/2022 06:03:10 PM |
|
#2244
|
|
New corporate slide set (5/18/22):
|
DewDiligence
|
05/19/2022 01:38:37 PM |
|
#2243
|
|
On the heels of this disappointing RSV trial,
|
vinmantoo
|
05/19/2022 11:43:24 AM |
|
#2242
|
|
ENTA’s phase-2b trial in RSV misses primary endpoint:
|
vinmantoo
|
05/19/2022 01:56:07 AM |
|
#2241
|
|
ENTA’s valuation:
|
DewDiligence
|
05/18/2022 06:37:04 PM |
|
#2239
|
|
Thoughts?
|
JK2016
|
05/18/2022 04:13:31 PM |
|
#2238
|
|
ENTA’s phase-2b trial in RSV misses primary endpoint:
|
DewDiligence
|
05/18/2022 04:09:41 PM |
|
#2237
|
|
NIH wants_to_study longer treatment_course for Paxlovid:
|
vinmantoo
|
05/18/2022 12:54:49 PM |
|
#2236
|
|
NIH wants_to_study longer treatment_course for Paxlovid:
|
DewDiligence
|
05/18/2022 12:48:57 PM |
|
#2235
|
|
@George Rho
|
vinmantoo
|
05/18/2022 12:41:36 PM |
|
#2234
|
|
I added last week at about $50.00
|
vinmantoo
|
05/18/2022 12:34:55 PM |
|
#2233
|
|
I added last week at about $50.00
|
willyw
|
05/18/2022 11:07:36 AM |
|
#2232
|
|
Out of Ignorance profile picture
|
willyw
|
05/18/2022 10:45:41 AM |
|
#2231
|
|
George Rho profile picture
|
willyw
|
05/18/2022 10:44:58 AM |
|
#2230
|
|
A very worthwhile reply to the article is
|
DewDiligence
|
05/18/2022 10:36:44 AM |
|
#2229
|
|
https://seekingalpha.com/article/4512678-enanta-slow-drip
A very worth while
|
willyw
|
05/18/2022 10:34:35 AM |
|
#2227
|
|
Thoughts on this post on “seeking alpha”
“Enanta: Slow
|
JK2016
|
05/18/2022 08:43:19 AM |
|
#2226
|
|
ENTA’s enterprise value at the current share price
|
vinmantoo
|
05/17/2022 09:05:44 PM |
|
#2225
|
|
ENTA’s enterprise value at the current share price
|
DewDiligence
|
05/11/2022 07:02:30 PM |
|
#2224
|
|
ENTA’s fully-diluted share count @3/31/22=24.7M—unchanged since 12/31/21
|
DewDiligence
|
05/11/2022 06:58:02 PM |
|
#2223
|
|
ENTA’s pro forma cash @3/31/22=$353.3M—a decrease of $24.4M
|
DewDiligence
|
05/11/2022 06:57:35 PM |
|
#2222
|
|
The main difference between the latest slide set
|
DewDiligence
|
05/10/2022 03:30:20 PM |
|
#2221
|
|
I too noticed the lack of a meaningful
|
DewDiligence
|
05/10/2022 12:59:05 PM |
|
#2220
|
|
Thanks Dew.
|
vinmantoo
|
05/10/2022 12:47:10 PM |
|
#2218
|
|
ENTA new corporate slide set (5/9/22):
|
DewDiligence
|
05/10/2022 11:31:29 AM |
|
#2217
|
|
ENTA FY2Q22 CC transcript:
|
DewDiligence
|
05/10/2022 11:29:19 AM |
|
#2216
|
|
ENTA FY2Q22* financials—royalty_revenue=$18.7M—3/31/22_cash=$322.5M (down from $
|
DewDiligence
|
05/09/2022 04:06:52 PM |
|
#2215
|
|
Paxlovid misses primary endpoint in post-exposure prophylaxis:
|
DewDiligence
|
04/29/2022 06:31:44 PM |
|
#2214
|
|
Thanks.
|
willyw
|
04/29/2022 01:25:09 PM |
|
#2213
|
|
He’s using the word, inoculation to mean infection
|
DewDiligence
|
04/29/2022 01:19:19 PM |
|
#2212
|
|
I'm still just trying to unpack the first tweet?!?
|
willyw
|
04/29/2022 01:05:28 PM |
|
#2211
|
|
Sounds like he's confused; he has a lot
|
DewDiligence
|
04/29/2022 11:30:15 AM |
|
#2210
|
|
If you think about the body as consisting
|
vinmantoo
|
04/29/2022 10:33:02 AM |
|
#2209
|
|
Use of a P-glycoprotein inhibitor (https://twitter.com/Biohazard3737/status/1519
|
DewDiligence
|
04/29/2022 08:15:26 AM |
